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Abstract
Context—The scarcity of cross-national reports and the changes in DSM-5 regarding panic 
disorder (PD) and panic attacks (PAs) call for new epidemiological data on PD and PAs and its 
subtypes in the general population.
Objective—To present representative data about the cross-national epidemiology of PD and PAs 
in accordance with DSM-5 definitions.
Design and Setting—Nationally representative cross-sectional surveys using the World Health 
Organization Composite International Diagnostic Interview version 3.0.
Participants—Respondents (n=142,949) from 25 high, middle and lower-middle income 
countries across the world aged 18 years or older.
Main Outcome Measures—PD and presence of single and recurrent PAs.
Results—Lifetime prevalence of PAs was 13.2% (s.e. 0.1%). Among persons that ever had a PA, 
the majority had recurrent PAs (66.5%; s.e. 0.5%), while only 12.8% fulfilled DSM-5 criteria for 
PD. Recurrent PAs were associated with a subsequent onset of a variety of mental disorders (OR 
2.0; 95% CI 1.8–2.2) and their course (OR 1.3; 95% CI 1.2–2.4) whereas single PAs were not (OR 
1.1; 95% CI 0.9–1.3 and OR 0.7; 95% CI 0.6–0.8). Cross-national lifetime prevalence estimates 
were 1.7% (s.e. 0.0%) for PD with a median age of onset of 32 (IQR 20–47). Some 80.4% of 
persons with lifetime PD had a lifetime comorbid mental disorder.
Conclusions—We extended previous epidemiological data to a cross-national context. The 
presence of recurrent PAs in particular is associated with subsequent onset and course of mental 
disorders beyond agoraphobia and PD, and might serve as a generic risk marker for 
psychopathology.
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Anxiety disorders are among the major contributors to the worldwide burden of disease 
(1,2). Among the anxiety disorders, panic disorder (PD) defined by the presence of 
recurrent, unexpected panic attacks (PAs) is of specific interest. However, epidemiological 
data regarding PD and PAs is limited and only few available studies have distinguished 
between PAs and PD, and within PAs, between single versus recurrent attacks (3,4). Also, 
most of the available epidemiological data comes from studies performed solely in the US 
(5–9), but it is especially important to study the characteristics of PD and PA cross-
nationally given the evidence that the prevalence of PD differs substantially across cultures 
(10). In the only cross-national account, that took place more than 20 years ago, only PD 
(using DSM-III criteria) and not PAs were studied (10).
In a review of the literature by Craske et al (4), several recommendations were made 
regarding the diagnostic criteria for PAs and PD, which were followed to a large extent in 
the Diagnostic and Statistical Manual version 5 (DSM-5). Importantly, the diagnosis of PD 
became no longer linked to the presence or absence of agoraphobia (AGO) as was done in 
DSM-IV. Also, the presence of PAs in DSM-5 was reframed as a generic symptom specifier 
that can be added to each of the diagnoses in DSM-5 and thus became no longer restricted to 
PD or AGO (3). This change was based among others on a series of studies suggesting PAs 
being associated with many mental disorders (e.g. anxiety and mood disorders, psychosis 
and substance abuse) and not with PD or AGO alone (4,12). Also, the presence of PAs was 
found to increase symptom severity, comorbidity rates and suicide, while negatively 
impacting treatment response in a number of disorders (4).
These changes regarding PD and PAs in DSM-5 call for new epidemiological data. In the 
present study we report on data regarding the epidemiology of PD from 25 lower-middle, 
middle, and high income countries. In addition, we report on data regarding PAs and their 
association with onset and course of mental disorders as this will further inform us about the 
utility of PAs as a risk marker for psychopathology. We specifically distinguished between 
single and recurrent PAs in this context as only very few studies are available on this issue. 
Given the importance of worrying about next PAs, we expected that particularly recurrent 
PAs would be associated with onset and course of mental disorders, in line with the DSM-IV 
field trial by Horwath et al (12). We used data from the World Mental Health Surveys (13).
Method
Samples
The WMH surveys included data from the low/lower-middle income countries of Colombia, 
Iraq, Nigeria, Peru, the People’s Republic of China – Beijing and Shanghai, and Ukraine, the 
upper-middle income countries of Brazil, Bulgaria, Colombia (Medellin), Lebanon, Mexico, 
and Romania, and the high income countries of Australia, Belgium, France, Germany, Israel, 
Italy, Japan, New Zealand, Northern Ireland, Poland, Portugal, Spain, Spain – Murcia, the 
Netherlands, and the United States. Most surveys used stratified multistage clustered area 
probability household sampling with no substitution for non-participants. Data collection 
took place between 2001 and 2012, and response rates ranged from 45.9 to 97.2%, with an 
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average of 69.0% (Table 1). Classification of countries into income categories (low-lower, 
upper-middle, high) was based on World Bank criteria (14).
Assessment of mental disorders
All WMH surveys were conducted face-to-face by lay interviewers who had received 
standardized training. Standardized translation, back-translation, harmonization and quality 
control procedures were applied for each of the participating surveys (13,15). Informed 
consent was obtained according to protocols endorsed by local Institutional Review Boards. 
The presence of mental disorders was assessed using the World Health Organization (WHO) 
Composite International Diagnostic Interview (CIDI) version 3.0. All respondents 
completed Part 1 of the WHO CIDI (13) which assesses lifetime mood disorders (major 
depressive episode and/or dysthymia, bipolar disorder), anxiety disorders (panic disorder, 
agoraphobia, specific phobia, social phobia, generalized anxiety disorder, post-traumatic 
stress disorder), substance use disorders (alcohol and drug abuse with or without 
dependence) and impulse control disorder (intermittent explosive disorder, binge-eating 
disorder and bulimia nervosa). Diagnostic hierarchy and organic exclusion rules were 
applied for all diagnoses other than substance abuse (with or without dependence). A 
probing strategy was used to assess age of onset for each of the disorders (15). A blinded 
clinical reappraisal study using the Structured Clinical Interview for DSM-IV (SCID) (16) 
found good diagnostic concordance between CIDI and SCID diagnoses. For panic disorder, 
this was indicated by an area under the curve of 0.72 (17).
Part I data were weighted to adjust for the differential probability of being selected and the 
socio-demographic and geographic structure of each sample. Respondents with a Part I 
disorder and an additional probability sub-sample were administered Part II of the survey, 
which assessed a number of other disorders and correlates. Further weightings were applied 
to the Part II data to adjust for the differential selection procedure and to match base 
population distributions on socio-demographic and geographic data.
Panic attacks in DSM-IV and DSM-5
In DSM-IV (18), criteria for PA consisted of a discrete period of intense fear or discomfort, 
in which four (or more) of the following symptoms develop abruptly and reach a peak within 
10 minutes:1) palpitations, pounding heart, or accelerated heart rate, 2) sweating, 3) 
trembling or shaking, 4) sensations of shortness of breath or smothering, 5) feeling of 
choking, 6) chest pain or discomfort, 7) nausea or abdominal distress, 8) feeling dizzy, 
unsteady, lightheaded, or faint, 9) derealization (feelings of unreality) or depersonalization 
(being detached from oneself), 10) fear of losing control or going crazy, 11) fear of dying, 
12) paresthesias (numbness or tingling sensations), 13) chills or hot flushes. PAs were not 
distinguished as a codable disorder, but only coded in the specific diagnosis in which the PA 
occurred (e.g. panic disorder with agoraphobia).
In DSM-5, the essential features of the PA specifier remained unchanged, although the 
DSM-IV terminology for describing different types of PAs (i.e., situationally bound/cued, 
situationally predisposed, and unexpected/uncued) was replaced with the terms unexpected 
(out of the blue) and expected PA. PAs function as a specifier and prognostic factor for 
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severity of diagnosis, course, and comorbidity across an array of disorders, including but not 
limited to anxiety disorders. Hence, PAs can be listed as a specifier applicable to any of the 
DSM-5 disorders. In the CIDI 3.0, the presence of panic attacks was probed before the 
diagnosis of PD, as was information on whether the attacks were single or recurrent, 
expected or unexpected, therefore PAs could be unlinked from PD.
Panic Disorder in DSM-IV and DSM-5
In DSM-IV, diagnostic criteria for Panic Disorder With or Without Agoraphobia include (1) 
recurrent, unexpected PAs and (2) at least one of the attacks has been followed by 1 month 
(or more) of one (or more) of the following: (a) persistent concern about having additional 
attacks, (b) worry about the implications of the attack or its consequences (e.g., losing 
control, having a heart attack, “going crazy”), (c) a significant change in behavior related to 
the attacks. In addition, it is coded whether PD occurred in the presence or absence of 
agoraphobia. Finally, it is checked that PAs are not due to the direct physiological effects of 
a substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hyperthyroidism), and whether PAs are not better accounted for by another mental disorder, 
such as social phobia (e.g., occurring on exposure to feared social situations), specific 
phobia (e.g., on exposure to a specific phobic situation), obsessive-compulsive disorder (e.g., 
on exposure to dirt in someone with an obsession about contamination), posttraumatic stress 
disorder (e.g., in response to stimuli associated with a severe stressor), or separation anxiety 
disorder (e.g., in response to being away from home or close relatives).
In DSM-5, diagnostic criteria were changed in that PD and agoraphobia are unlinked. 
Essentially, the former DSM-IV diagnoses of PD with agoraphobia, PD without 
agoraphobia, and agoraphobia without history of PD have been replaced by two diagnoses, 
PD and agoraphobia, each with separate criteria. DSM-5 PD consists of the presence of 
recurrent unexpected panic attacks, as defined previously. The additional criteria regarding 
concerns, maladaptive behaviors and exclusion criteria (due to physiological effects or better 
explained by other mental disorders) were somewhat reworded but largely kept in line with 
DSM-IV. In CIDI 3.0, since the criteria regarding PD and agoraphobia were scored first and 
the specific diagnoses were made later, PD could be unlinked from agoraphobia to arrive at 
DSM-5 compatible PD diagnosis.
Socio-demographic variables
Socio-demographic variables included age at interview, ages of onset of PA and PD, sex, 
education, employment status, marital status, and household income based on country-
specific quartiles of gross household earnings in the past 12 months (19).
Statistical analysis
We determined rates of lifetime PAs split into persons with and without lifetime PD. Among 
persons with lifetime PAs without lifetime PD, we distinguished between persons with 
single and recurrent PAs. Of persons with lifetime diagnosis of PD and of those with a 
lifetime presence of PAs, we determined the proportion of persons with 12-month 
prevalence of PD and PAs, as an indicator of the chronicity of PD and PAs. Similarly, 
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persons with 12-month prevalent PD and PAs were split into persons with and without 30-
day prevalence of PD and PAs.
Prevalence rates were compared across countries, World Bank income groups, and WHO 
regions using the Chi-square test of homogeneity. In addition, the estimated proportion of 
the population who will have the disorder at age 75 (projected risk) was calculated using 
survival analysis on the basis of age of onset data (except for four of the surveys were age 
was restricted to 18–65). Specific analyses comparing single versus recurrent PAs in their 
association with other (phobic) disorders were done. For analyses examining whether PAs 
predict onset and course of psychiatric disorders, we used PAs in the absence of PD, as 
otherwise they would count as being part of a comorbid psychiatric disorder (PD).
Logistic regression and survival analyses were used to examine sociodemographic 
correlates. Survival analysis was used to estimate age of onset (AOO) and projected lifetime 
risk. The actuarial method implemented in SAS 9.4 was used to generate the AOO curves. 
Significance was calculated using Wald and McNemar’s Chi-square tests. Because the data 
were weighted and clustered, the Taylor series linearization method (20) implemented in the 
SUDAAN software package (11.0) (21) was used to estimate design-based standard errors. 
Statistical significance was consistently evaluated using two-sided tests, with P < 0.05 
considered significant.
Results
Prevalence, age of onset, and lifetime risk of PA and PD
Lifetime prevalence of PAs for all countries combined was 13.2% (se. 0.1%) (Table 2). Of 
the persons with lifetime PA, 12.8% had lifetime PD, for a population-level lifetime 
prevalence of PD of 1.7% (se. 0.0%) (i.e., 12.8% x13.2%). Of persons with lifetime PA 
without PD, about two thirds (66.5%; se. 0.5%) had recurrent PAs.
Significant differences in prevalence rates of PAs and PD were observed between country 
groups based on income level and on WHO regions, with higher prevalence rates in high 
income countries and countries in the region of the Americas, Western Pacific and Western 
Europe. Twelve month prevalence rates of PAs and PD were 4.9% (se. 0.1%) and 1.0% (se. 
0.0%) respectively (appendix Table 1). Some 34.5% (se. 0.5%) of persons with lifetime PAs 
without lifetime PD had PAs in the last twelve months. For PD, this figure was 57.1% (se. 
1.3%). Prevalence rates for last 30 days PAs and PD were 1.6% (se. 0.0%) and 0.4% (se. 
0.0%) respectively. Of persons with past 12 months prevalence of PAs without PD, 29.2% 
(se. 0.7%) had PAs in the last 30 days. For PD, this figure was 40.6% (se. 1.7%) (Appendix 
Table 2). Median age of onset of PAs was 34 years (IQR 20–51) and for PAs without PD this 
was 35 years (IQR 20–52), resulting in a projected risk at age 75 of 23.0% (se. 0.4) for PAs 
and 20.6% (se. 0.4) for PAs without PD. Median age-of-onset of PD was 32 years (IQR 20–
47). The age-of-onset distribution resulted in a projected risk of PD at age 75 of 2.7% (se. 
0.1%).
Lifetime co-morbidity with other mental disorders in persons with lifetime PD was 80.4% 
(se. 1.1%) (Appendix table 3). Co-morbidity levels were particularly high for other anxiety 
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disorders (63.1%, se 1.3%) and mood disorders (53.7%, se 1.4%), and considerably lower 
for substance abuse disorders (26.2% se 1.4%) and impulse controls disorders (10.4%, se 
0.7%). In persons with lifetime co-morbidity, onset of PD preceded the onset of the other 
disorders in a minority of cases (15.4%, se. 0.9%).
Socio-demographic correlates of PA and PD
Beloning to groups below 60, early age of onset, female gender, other employment status 
(largely unemployed), being divorced/separated/widowed, lower education, and having a 
low household income were associated with both PAs without PD and with PD (Appendix 
Tables 4 and 5). These correlates were largely comparable for the different income level 
country groups. Few differences were found when comparing risk factors for 30-day, 
lifetime, 12-month prevalence among lifetime, and 30-days prevalence among 12 months 
cases, suggesting that largely the same risk factors may operate for onset and course of PAs 
and PD. However, as an exception, gender was found to be related to onset of PAs and PD, 
but not to 30-day prevalence among those with a 12-month prevalent disorder.
PAs as a predictor of subsequent mental disorder onset and disorder course
In Table 3, we distinguished between single and recurrent PAs. Single PAs were generally 
not associated with subsequent mental disorders, with only some exceptions. In contrast, 
recurrent PAs were associated with increased odds of all included mental disorders. A 
comparable pattern of results, though less pronounced, emerged when predicting the rates of 
12-month cases among lifetime cases per disorder in order to estimate the associations of 
PAs with course of disorder. Here we found that single PAs appear generally slightly 
protective while recurrent PAs were associated with a worsened course.
Discussion
The goal of this study was to present the cross-national epidemiology of PAs and PD. The 
general findings were that DSM-5 lifetime prevalence for PD is 1.7% and its projected 
lifetime risk at age 75 is 2.7%. These findings are in line with previous cross-national 
estimates of 1.4–2.9% (11), while estimates based on American data alone were slightly 
higher than ours: 4.8%, 3.4% and 2.2% (7–9). The present study extends these findings to 25 
countries spread over several regions in the world and income groups. Significant variation 
in prevalence between countries was observed and this seemed to be both related to income 
differences and to regional differences. Consistent with previous reports (6,22,23), high 
levels of comorbidity were found for persons with PD. In the present study, as many as 
80.4% of persons with lifetime PD had a lifetime comorbid other mental disorder, 
particularly mood or anxiety disorder, and in only a minority of persons did PD precede the 
onset of any other disorder (15.4%). Previous reports have found panic as a comorbid 
disorder to be related to an adverse course of other mental disorders (24).
The lifetime prevalence of PAs was 13.2% in our sample, with a projected risk at age 75 of 
23.0%, making the presence of PAs a common phenomenon in the general population, as 
observed earlier (25,26). Still, these figures are lower than a previous report based on 
American data alone (7) (28.3%). Consistent with these findings however, in our cross-
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national sample, highest lifetime prevalence rates were found for the United States (27.3%) 
and New Zealand (27.4%). Comparable to the previous report on US data, most PAs occur in 
the absence of PD: 20.6% out of 23.0%.
Among persons that ever had a PA, the majority had recurrent PAs. Of interest, recurrent 
PAs were associated with a subsequent onset of a variety of mental disorders whereas single 
PAs were not. Also, only recurrent PAs were associated with higher rates of past 12 month 
disorders among persons with lifetime disorders. This pattern was seen for all mental 
disorders combined, and specifically for major depression/dysthymia and drug dependence. 
These findings seem to suggest that particularly the presence of recurrent PAs may be seen 
as a risk marker for general psychopathology – a suggestion made earlier with respect to PAs 
in general (12). This finding is of interest as in the review by Craske et al (2010), which 
served as the evidence base for the suggestion to use PAs as a generic specifier in DSM-5, it 
was stated that the issue is whether the presence of PAs would “predict treatment response, 
comorbidity or course of mental disorder”. In this study, we were able to address the latter 
two points and found that this seems to hold only for recurrent PAs.
The results of this study should be considered within the context of the following limitations 
and strengths. The WMH Surveys are essentially cross-sectional in nature and the 
retrospective assessment of mental disorders and their age of onset is likely to have resulted 
in inaccuracies in the prevalence of PAs and PD and the age of their onset. Although probing 
of age of onset was performed on the basis of validated techniques that facilitate accurate 
recall (27), some bias may have been introduced, probably in the form of underestimation 
(28). This may particularly be true for PAs which do not have the status of mental disorders 
and as such are not as extensively probed by multiple items, and their associated disability 
and treatment status was not scored. In this study, of the persons that ever experienced a PA, 
9.1% were not able to remember if they had single or recurrent PAs. We could therefore not 
address the point was would be the optimal cut-off for the number of PAs to predict later 
onset of mental disorders. Also, we could not address other subtypes of PAs to refine the PA 
specifier in DSM-5, such as symptom-based (29) or age of onset-based subtypes (30). Future 
research could address the utility of distinguishing between single versus recurrent PAs, and 
expected versus unexpected PAs, and symptom-based subtypes of PAs in terms of their 
associated disability and treatment status. Among the strengths of this study, the WMH 
surveys consist of cross-national samples whereas most reports have been based on a single, 
national study. This offered the possibility to look into differences between countries, and 
between groups of countries based on income levels and regions in the world. This strategy 
has resulted in a large sample of respondents that enabled us to explore in more detail 
specific subgroups of persons, such as those having PAs in the absence of PD and further 
dissection into the kind of PAs, without encountering power issues.
In sum, in this study we provided cross-national epidemiological data on DSM-5 PD and 
PAs, and found a cross-national lifetime prevalence of PD of 1.7% and an estimated risk at 
age 75 of 2.7%. For PAs, these figures were 13.2% and 23.0% respectively. We found that 
about two thirds of PAs were recurrent and that only recurrent PAs are associated with onset 
and course of a variety of mental disorders.
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12-month prevalence of panic attack (PA) and panic disorder (PD) in the World Mental 
Health surveys.
Country




























% SE % SE % SE % SE % SE
Low-Lower middle income 
countries
2,9 0,1 2,4 0,1 0,5 0,1 38,4 1,3 64,4 3,6 36498 36395
 Colombia 6,1 0,4 5,4 0,4 0,7 0,1 31,2 2,2 53,7 9,0 4426 4422
 Iraq 3,7 0,5 2,7 0,4 1,0 0,3 43,5 4,6 71,5 6,5 4332 4295
 Nigeria 1,3 0,2 1,1 0,2 0,1 0,1 46,7 5,3 76,2 16,1 6752 6713
 Peru 3,0 0,2 2,7 0,2 0,3 0,1 40,3 2,1 70,5 6,4 3930 3929
 PRC China 1,0 0,2 0,8 0,2 0,2 0,1 47,6 8,4 50,1 13,0 5201 5197
 PRC Shen Zhen 0,9 0,1 0,7 0,1 0,2 0,1 33,4 4,1 78,9 7,7 7132 7129
 Ukraine 6,2 0,4 4,8 0,3 1,4 0,3 42,6 2,4 64,4 6,2 4725 4710
Upper-middle income 4,3 0,2 3,7 0,2 0,7 0,1 36,4 1,2 62,1 3,5 28927 24565
 Brazil 5,1 0,3 4,0 0,3 1,0 0,2 40,2 2,2 61,8 8,2 5037 5023
 Bulgaria 2,7 0,3 2,2 0,3 0,6 0,1 43,7 4,4 53,5 5,4 5318 5301
 Colombia (Medellin) 7,1 0,7 6,1 0,6 0,9 0,2 32,6 2,4 73,8 7,2 3261 3260
 Lebanon 4,8 0,5 4,6 0,5 0,3 0,1 34,1 2,7 49,2 10,3 2857 2851
 Mexico 3,3 0,4 2,6 0,3 0,7 0,1 38,6 3,1 65,3 7,1 5782 5781
 Romania 4,7 0,4 4,2 0,4 0,4 0,1 32,0 3,3 63,3 12,1 2357 2349
High income countries 6,0 0,1 4,8 0,1 1,2 0,1 33,3 0,5 55,2 1,4 81839 81754
 Australia 7,3 0,4 5,5 0,4 1,8 0,2 30,8 1,7 50,0 3,9 8463 8461
 Belgium 3,5 0,7 2,7 0,5 0,9 0,3 31,4 4,0 54,6 11,4 2419 2417
 France 3,2 0,4 2,3 0,2 1,0 0,3 25,2 2,3 46,0 9,7 2894 2894
 Germany 3,2 0,4 2,5 0,4 0,7 0,2 28,9 3,3 46,9 7,2 3555 3555
 Israel 5,0 0,3 4,4 0,3 0,6 0,1 48,7 2,5 62,6 7,5 4859 4853
 Italy 2,7 0,3 2,1 0,3 0,7 0,1 32,1 3,4 42,5 5,8 4712 4708
 Japan 2,0 0,3 1,7 0,2 0,3 0,1 28,8 3,1 45,0 10,6 4129 4126
 New Zealand 9,2 0,3 7,5 0,3 1,7 0,1 30,5 1,1 60,3 3,2 12790 12781
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% SE % SE % SE % SE % SE
 Northern Ireland 9,5 0,5 7,2 0,5 2,3 0,2 34,1 1,8 70,7 3,6 4340 4335
 Poland 2,5 0,1 2,3 0,1 0,2 0,1 41,4 2,1 62,8 8,5 10081 10049
 Portugal 6,9 0,4 6,0 0,4 0,9 0,2 33,3 1,9 52,9 6,9 3849 3841
 Spain 3,7 0,3 3,1 0,3 0,6 0,1 36,9 2,7 49,2 6,8 5473 5472
 Spain (Murcia) 6,0 0,5 5,3 0,6 0,7 0,1 36,3 2,7 45,7 6,5 2621 2617
 The Netherlands 4,5 0,4 3,2 0,4 1,3 0,3 29,1 3,1 41,5 6,2 2372 2370
 The United States 10,7 0,4 8,0 0,4 2,7 0,2 35,2 1,2 57,9 3,0 9282 9275
All countries combined 4,9 0,1 4,0 0,1 1,0 0,0 34,5 0,5 57,1 1,3 147264 142714
WHO regionsb
 Region of the 6,5 0,2 5,2 0,2 1,3 0,1 35,3 0,8 60,0 2,4 31718 31690
 African Region 1,3 0,2 1,1 0,2 0,1 0,1 46,7 5,3 76,2 16,1 11067 6713
 Western Pacific 5,3 0,2 4,2 0,1 1,1 0,1 30,9 0,9 55,4 2,4 37715 37694
 Eastern 4,5 0,3 3,8 0,2 0,6 0,1 42,3 1,8 65,3 4,9 12048 11999
 Western European 4,9 0,1 3,9 0,1 1,0 0,1 32,8 0,9 52,5 2,2 32235 32209
 Eastern European 3,6 0,1 3,0 0,1 0,6 0,1 40,4 1,4 61,1 3,8 22481 22409














Comparison between low, 































Sample size used after excluding lifetime panic attack cases with missing age of onset.
b
Region of the Americas (Colombia, Mexico, Brazil, Peru, The United States, Medellin); African region (Nigeria); 
Western Pacific region (PRC Shen Zhen, PRC Beijing and Shanghai, Japan, Australia, New Zealand); Eastern 
Mediterranean region (Israel, Iraq, Lebanon); Western European region (Belgium, France, Germany, Italy, The 
Netherlands, Spain, Northern Ireland, Portugal, Murcia); Eastern European region (Romania, Bulgaria, Poland, Ukraine).
c
Chi-square test of homogeneity to determine if there is variation in prevalence estimates across countries.
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30-day prevalence of panic attack (PA) and panic disorder (PD) in the World Mental Health 
surveys.
Country
Among the total population




















% SE % SE % SE % SE % SE
Low-Lower middle 1,0 0,1 0,8 0,1 0,3 0,0 32,4 1,9 50,4 4,7 36498 36395
 Colombia 1,6 0,2 1,3 0,2 0,3 0,1 24,9 3,2 44,8 10,6 4426 4422
 Iraq 1,9 0,3 1,2 0,3 0,7 0,3 45,1 7,0 71,4 10,3 4332 4295
 Nigeria 0,3 0,1 0,3 0,1 0,0 0,0 24,6 7,2 17,2 14,0 6752 6713
 Peru 0,9 0,1 0,8 0,1 0,1 0,0 30,8 4,8 35,6 13,1 3930 3929
 PRC China 0,3 0,1 0,3 0,1 0,1 0,1 30,4 7,6 36,3 22,4 5201 5197
 PRC Shen Zhen 0,3 0,1 0,3 0,1 0,1 0,0 34,6 9,3 36,1 14,6 7132 7129
 Ukraine 2,5 0,3 1,8 0,2 0,7 0,2 37,1 2,9 52,4 6,3 4725 4710
Upper-middle income 1,4 0,1 1,2 0,1 0,3 0,0 31,7 1,9 38,9 4,8 28927 24565
 Brazil 1,7 0,2 1,3 0,2 0,4 0,1 32,9 3,6 37,0 8,8 5037 5023
 Bulgaria 1,2 0,2 0,9 0,2 0,3 0,1 41,0 5,6 49,4 11,4 5318 5301
 Colombia (Medellin) 1,7 0,3 1,4 0,2 0,3 0,1 22,9 3,6 34,1 11,1 3261 3260
 Lebanon 1,5 0,3 1,4 0,3 0,1 0,1 31,0 5,0 33,0 16,4 2857 2851
 Mexico 1,0 0,2 0,7 0,1 0,2 0,1 28,5 4,4 30,9 8,9 5782 5781
 Romania 2,1 0,3 1,8 0,3 0,3 0,1 42,2 5,9 67,6 21,2 2357 2349
High income countries 1,8 0,1 1,3 0,1 0,5 0,0 27,9 0,8 39,1 2,0 81839 81754
 Australia 1,9 0,2 1,3 0,2 0,6 0,1 24,3 2,6 33,0 4,9 8463 8461
 Belgium 1,2 0,5 0,8 0,3 0,5 0,3 28,9 8,3 50,8 15,8 2419 2417
 France 0,8 0,2 0,5 0,1 0,2 0,1 24,3 5,2 22,6 10,3 2894 2894
 Germany 1,0 0,2 0,6 0,1 0,4 0,2 23,3 4,5 53,1 12,0 3555 3555
 Israel 1,4 0,2 1,3 0,2 0,2 0,1 28,3 3,2 32,8 8,8 4859 4853
 Italy 1,0 0,2 0,7 0,2 0,3 0,1 31,8 5,9 46,5 9,8 4712 4708
 Japan 0,5 0,1 0,3 0,1 0,2 0,1 20,3 5,7 46,2 14,1 4129 4126
 New Zealand 2,9 0,2 2,2 0,2 0,7 0,1 29,3 1,7 41,3 3,8 12790 12781
 Northern Ireland 3,3 0,3 2,2 0,2 1,1 0,2 30,9 3,0 45,8 4,8 4340 4335
 Poland 0,7 0,1 0,6 0,1 0,0 0,0 26,7 3,0 19,4 9,4 10081 10049
 Portugal 2,0 0,2 1,7 0,2 0,4 0,1 27,8 2,8 39,0 10,7 3849 3841
 Spain 1,2 0,2 1,0 0,2 0,3 0,1 30,9 4,9 47,1 7,8 5473 5472
 Spain (Murcia) 1,6 0,4 1,4 0,3 0,2 0,1 27,0 5,0 28,2 14,3 2621 2617
 The Netherlands 1,3 0,4 0,7 0,3 0,5 0,2 23,0 7,2 43,2 11,4 2372 2370
 The United States 3,3 0,2 2,2 0,2 1,0 0,1 28,0 1,9 38,1 4,6 9282 9275
de Jonge et al. Page 12














Among the total population




















% SE % SE % SE % SE % SE
All countries combined 1,6 0,0 1,2 0,0 0,4 0,0 29,2 0,7 40,6 1,7 147264 142714
WHO regionsb
 Region of the 1,9 0,1 1,4 0,1 0,5 0,1 27,8 1,3 37,4 3,4 31718 31690
 African Region 0,3 0,1 0,3 0,1 0,0 0,0 24,6 7,2 17,2 14,0 11067 6713
 Western Pacific 1,6 0,1 1,2 0,1 0,4 0,0 27,7 1,4 38,0 2,9 37715 37694
 Eastern 1,6 0,2 1,3 0,1 0,4 0,1 33,3 2,8 53,8 7,9 12048 11999
 Western European 1,5 0,1 1,1 0,1 0,4 0,0 28,5 1,5 43,0 3,2 32235 32209
 Eastern European 1,3 0,1 1,1 0,1 0,3 0,1 34,9 1,9 47,6 5,2 22481 22409














Comparison between low, 

































Sample size used after excluding lifetime panic attack cases with missing age of onset.
b
Region of the Americas (Colombia, Mexico, Brazil, Peru, The United States, Medellin); African region (Nigeria); 
Western Pacific region (PRC Shen Zhen, PRC Beijing and Shanghai, Japan, Australia, New Zealand); Eastern 
Mediterranean region (Israel, Iraq, Lebanon); Western European region (Belgium, France, Germany, Italy, The 
Netherlands, Spain, Northern Ireland, Portugal, Murcia); Eastern European region (Romania, Bulgaria, Poland, Ukraine).
c
Chi-square test of homogeneity to determine if there is variation in prevalence estimates across countries.
Appendix Table 3
Comorbidity of panic disorder with other mental disorders.













% SE % SE % SE % SE % SE
Lifetime comorbiditya
 Lifetime 53,7 1,4 63,1 1,3 10,4 0,7 26,2 1,4 80,4 1,1
 12-month 55,4 1,7 64,9 1,7 12,2 1,1 28,1 1,7 81,8 1,5
12-month comorbidityb
 12-month 43,6 1,8 57,6 1,8 8,1 0,8 11,2 1,3 71,7 1,6
Temporal priority of panic disorderc
 Lifetime 33,0 1,8 15,2 1,4 36,9 3,1 45,8 3,2 15,4 0,9
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% SE % SE % SE % SE % SE
 12-month 35,1 2,2 17,3 2,0 34,4 3,4 51,1 3,8 15,7 1,3
a
Percentage of respondents with either lifetime or 12 month panic disorder who also meet lifetime criteria for at least one 
of the other disorders.
b
Percentage of respondents with 12 month panic disorder who also meet 12 month criteria for at least one of the other 
disorders.
c
Percentage of respondents with either lifetime or 12 month panic disorder and at least 1 of the other disorders, whose age 
of onset of panic disorder is reported to be younger than the age of onset of all comorbid disorders under consideration (ie, 
either mood, anxiety, substance use, impulse control or any disorder).
Appendix Table 4
Bivariate associations between socio-demographics and panic disorder.
Correlates







OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age-cohort
 18–29 1.7* (1.2–2.4) 6.4* (5.2–7.7)
 30–44 2.0* (1.5–2.6) 5.0* (4.2–5.8)
 45–59 1.6* (1.2–2.1) 3.0* (2.6–3.6)
 60+ 1 1





 Early 2.2* (1.6–3.0) 1,2 (0.8–1.7)
 Early-average 1,3 (0.9–1.7) 1,2 (0.8–1.8)
 Late-average 0,9 (0.7–1.1) 0,9 (0.6–1.3)
 Late 1 1










 Female 2.0* (1.6–2.5) 1.8* (1.6–2.0) 1,2 (1.0–1.5) 1 (0.7–1.3)
 Male 1 1 1 1









 Student 1,1 (0.6–2.0) 1,3 (0.9–1.8) 1,8 (0.9–3.8) 1 (0.4–2.1)
 Homemaker 1.4* (1.0–2.0) 1.4* (1.2–1.6) 1.5* (1.1–2.0) 0,8 (0.5–1.2)
 Retired 1,1 (0.8–1.6) 1.3* (1.0–1.6) 1.5* (1.0–2.2) 1,1 (0.7–1.8)
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OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
 Other 3.0* (2.3–4.1) 2.0* (1.7–2.4) 2.2* (1.6–3.2) 1.5* (1.0–2.1)
 Employed 1 1 1 1









 Never married 1,1 (0.8–1.4) 1.3* (1.2–1.5) 1,2 (0.9–1.6) 1,2 (0.8–1.7)
 Divorced/separated/widowed 2.6* (2.0–3.4) 1.7* (1.5–1.9) 1.6* (1.2–2.1) 1.5* (1.1–2.1)
 Currently married 1 1 1 1









 No education 3.8* (1.3–11.4) 1,6 (0.9–2.6) 4.2* (1.8–10.2) 2,3 (0.8–6.9)
 Some primary 5.7* (3.6–8.9) 1.8* (1.4–2.2) 2.9* (1.7–5.0) 4.0* (2.2–7.5)
 Finished primary 5.0* (2.9–8.6) 2.2* (1.8–2.8) 1.7* (1.1–2.6) 2.6* (1.5–4.7)
 Some secondary 2.9* (2.0–4.1) 1.8* (1.5–2.1) 1.5* (1.0–2.1) 2.0* (1.3–3.0)
 Finished secondary 2.6* (1.8–3.8) 1.7* (1.4–1.9) 1,3 (0.9–1.8) 1.8* (1.2–2.8)
 Some college 2.0* (1.4–2.8) 1.5* (1.3–1.8) 0,9 (0.7–1.3) 1.8* (1.2–2.8)
 Finished college 1 1 1 1









 Low 1.8* (1.3–2.4) 1.5* (1.3–1.7) 1.5* (1.1–2.1) 1,2 (0.8–1.8)
 Low-average 1,3 (1.0–1.8) 1.2* (1.1–1.4) 1,3 (0.9–1.7) 1 (0.7–1.5)
High-average 1,1 (0.8–1.5) 1,1 (1.0–1.3) 0,9 (0.7–1.3) 1 (0.7–1.5)
 High 1 1 1 1








Ne 142949 6250338 2563 1465
*
Significant at the .05 level, 2 sided test.
a
These estimates are based on logistic regression models adjusted for age, gender and country.
b
These estimates are based on survival models adjusted for age-cohorts, gender, person-years and country.
c
These estimates are based on logistic regression models adjusted for time since panic disorder onset, age of panic disorder 
onset, gender and country.
d
Chi square test of significant differences between blocks of sociodemographic variables.
e
Denominator N: 142,949 = total sample; 6,250,338 = number of person-years in the survival models; 2,563 = number of 
lifetime cases of panic disorder; 1,465 = number of 12-month cases of panic disorder.
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OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age-cohort
 18–29 1.5* (1.2–1.8) 5.1* (4.7–5.6)
 30–44 1.6* (1.3–1.9) 3.2* (2.9–3.4)
 45–59 1.5* (1.2–1.8) 2.1* (2.0–2.3)
 60+ 1,0 1,0





 Early 1.5* (1.3–1.7) 0,9 (0.7–1.2)
 Early-average 1,1 (1.0–1.3) 0.7* (0.6–0.9)
 Late-average 0,9 (0.8–1.0) 0,9 (0.7–1.1)
 Late 1,0 1,0




Time since onset (Continuous) 0.98* (0.97–0.98) 1.01* (1.00–1.01)
χ21 = 183.6*,
P <.001
χ21 = 8.8* P = 
0.003
Gender
 Female 2.0* (1.7–2.3) 1.6* (1.5–1.7) 1.4* (1.2–1.5) 1,0 (0.9–1.2)
 Male 1,0 1,0 1,0 1,0









 Student 1,1 (0.8–1.5) 1,1 (1.0–1.3) 1,2 (0.9–1.5) 1,0 (0.7–1.5)
 Homemaker 1.3* (1.1–1.6) 1,1 (1.0–1.1) 1,2 (1.0–1.3) 1,2 (0.9–1.5)
 Retired 1,0 (0.8–1.3) 1,0 (0.9–1.1) 1.4* (1.2–1.6) 0,8 (0.6–1.1)
 Other 1.9* (1.6–2.3) 1.4* (1.3–1.5) 1.7* (1.5–2.0) 1,1 (0.9–1.3)
 Employed 1,0 1,0 1,0 1,0









 Never married 1,1 (0.9–1.3) 1.1* (1.0–1.2) 1.1* (1.0–1.3) 1.2* (1.0–1.5)
 Divorced/separated/widowed 1.4* (1.2–1.7) 1.2* (1.1–1.3) 1.2* (1.1–1.3) 1,1 (0.9–1.3)
 Currently married 1,0 1,0 1,0 1,0
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OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
 No education 2.5* (1.5–4.2) 1.7* (1.4–2.0) 1.7* (1.1–2.5) 1,3 (0.7–2.3)
 Some primary 1.9* (1.5–2.5) 1.5* (1.4–1.7) 2.0* (1.6–2.5) 0,8 (0.6–1.2)
 Finished primary 2.0* (1.5–2.6) 1.4* (1.3–1.6) 1.8* (1.5–2.2) 1,0 (0.7–1.4)
 Some secondary 1.5* (1.2–1.9) 1.2* (1.1–1.3) 1.4* (1.2–1.6) 1,0 (0.8–1.3)
 Finished secondary 1.3* (1.1–1.6) 1.2* (1.1–1.3) 1.3* (1.1–1.4) 1,0 (0.8–1.2)
 Some college 1,2 (1.0–1.6) 1.2* (1.1–1.3) 1.2* (1.0–1.4) 1,0 (0.8–1.3)
 Finished college 1,0 1,0 1,0 1,0









 Low 1.6* (1.3–2.0) 1.1* (1.0–1.2) 1.5* (1.3–1.7) 1.4* (1.1–1.7)
 Low-average 1.4* (1.1–1.7) 1.1* (1.0–1.2) 1.2* (1.1–1.4) 1,2 (0.9–1.5)
 High-average 1.4* (1.1–1.7) 1,0 (1.0–1.1) 1.2* (1.0–1.3) 1,3 (1.0–1.6)
 High 1,0 1,0 1,0 1,0








N e 138281 5843592 12730 4971
*
Significant at the .05 level, 2 sided test.
a
These estimates are based on logistic regression models adjusted for age, gender and country.
b
These estimates are based on survival models adjusted for age-cohorts, gender, person-years and country.
c
These estimates are based on logistic regression models adjusted for time since panic attack onset, age of panic attack 
onset, gender and country.
d
Chi square test of significant differences between blocks of sociodemographic variables.
e
Denominator N: 138,281 = total sample; 5,843,592 = number of person-years in the survival models; 12,730 = number of 
lifetime panic attack without lifetime panic disorder cases; 4,971 = number of 12-month panic attack without lifetime panic 
disorder cases.
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